Literature DB >> 26669862

It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research.

Ruth Perets1, Ronny Drapkin2.   

Abstract

Hereditary breast and ovarian cancer syndrome carries significant mortality for young women if effective preventive and screening measures are not taken. Preventive salpingo-oophorectomy is currently the only method known to reduce the risk of ovarian cancer-related death. Histopathological analyses of these surgical specimens indicate that a high proportion of ovarian cancers in women at high risk and in the general population arise from the fallopian tube. This paradigm shift concerning the cell of origin for the most common subtype of ovarian cancer, high-grade serous carcinoma, has sparked a major effort within the research community to develop new and robust model systems to study the fallopian tube epithelium as the cell of origin of "ovarian" cancer. In this review, evidence supporting the fallopian tube as the origin of ovarian cancer is presented as are novel experimental model systems for studying the fallopian tube epithelium in high-risk women as well as in the general population. This review also addresses the clinical implications of the newly proposed cell of origin, the clinical questions that arise, and novel strategies for ovarian cancer prevention. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 26669862      PMCID: PMC4703449          DOI: 10.1158/0008-5472.CAN-15-1382

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

1.  Opportunistic and interventional salpingectomy in women at risk: a strategy for preventing pelvic serous cancer (PSC).

Authors:  M W Kamran; D Vaughan; D Crosby; N A Wahab; F A Saadeh; N Gleeson
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2013-07-21       Impact factor: 2.435

2.  Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations.

Authors:  James R Conner; Emily Meserve; Ellen Pizer; Judy Garber; Michael Roh; Nicole Urban; Charles Drescher; Bradley J Quade; Michael Muto; Brooke E Howitt; Mark D Pearlman; Ross S Berkowitz; Neil Horowitz; Christopher P Crum; Colleen Feltmate
Journal:  Gynecol Oncol       Date:  2013-12-12       Impact factor: 5.482

3.  Salpingectomy to prevent ovarian cancer: A Countercurrents Series.

Authors:  S A Narod
Journal:  Curr Oncol       Date:  2013-06       Impact factor: 3.677

4.  Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.

Authors:  C B Powell; E M Swisher; I Cass; J McLennan; B Norquist; R L Garcia; J Lester; B Y Karlan; L Chen
Journal:  Gynecol Oncol       Date:  2013-02-04       Impact factor: 5.482

5.  Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study.

Authors:  Kala Visvanathan; Russell Vang; Patricia Shaw; Amy Gross; Robert Soslow; Vinita Parkash; Ie-Ming Shih; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2011-12       Impact factor: 6.394

6.  BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.

Authors:  Amy Finch; Gareth Evans; Steven A Narod
Journal:  Womens Health (Lond)       Date:  2012-09

7.  Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications.

Authors:  Joseph W Carlson; Elke A Jarboe; David Kindelberger; Marisa R Nucci; Michelle S Hirsch; Christopher P Crum
Journal:  Int J Gynecol Pathol       Date:  2010-07       Impact factor: 2.762

8.  High-grade serous ovarian cancer arises from fallopian tube in a mouse model.

Authors:  Jaeyeon Kim; Donna M Coffey; Chad J Creighton; Zhifeng Yu; Shannon M Hawkins; Martin M Matzuk
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-13       Impact factor: 11.205

9.  Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.

Authors:  Amir A Jazaeri; Jennifer L Bryant; Hong Park; Hui Li; Neetu Dahiya; Mark H Stoler; James Stuart Ferriss; Anindya Dutta
Journal:  Neoplasia       Date:  2011-10       Impact factor: 5.715

10.  In vitro three-dimensional modeling of fallopian tube secretory epithelial cells.

Authors:  Kate Lawrenson; Maria Notaridou; Nathan Lee; Elizabeth Benjamin; Ian J Jacobs; Christopher Jones; Simon A Gayther
Journal:  BMC Cell Biol       Date:  2013-09-27       Impact factor: 4.241

View more
  52 in total

Review 1.  Preclinical Models of Ovarian Cancer: Pathogenesis, Problems, and Implications for Prevention.

Authors:  Anthony N Karnezis; Kathleen R Cho
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

2.  Microvesicle Proteomic Profiling of Uterine Liquid Biopsy for Ovarian Cancer Early Detection.

Authors:  Georgina D Barnabas; Keren Bahar-Shany; Stav Sapoznik; Limor Helpman; Yfat Kadan; Mario Beiner; Omer Weitzner; Nissim Arbib; Jacob Korach; Tamar Perri; Guy Katz; Anna Blecher; Benny Brandt; Eitan Friedman; David Stockheim; Ariella Jakobson-Setton; Ram Eitan; Shunit Armon; Hadar Brand; Oranit Zadok; Sarit Aviel-Ronen; Michal Harel; Tamar Geiger; Keren Levanon
Journal:  Mol Cell Proteomics       Date:  2019-02-13       Impact factor: 5.911

3.  Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C.

Authors:  Alexia T Kedves; Scott Gleim; Xiaoyou Liang; Dennis M Bonal; Frederic Sigoillot; Fred Harbinski; Sneha Sanghavi; Christina Benander; Elizabeth George; Prafulla C Gokhale; Quang-De Nguyen; Paul T Kirschmeier; Robert J Distel; Jeremy Jenkins; Michael S Goldberg; William C Forrester
Journal:  J Clin Invest       Date:  2017-11-13       Impact factor: 14.808

4.  New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination.

Authors:  Lan G Coffman; Daniela Burgos-Ojeda; Rong Wu; Kathleen Cho; Shoumei Bai; Ronald J Buckanovich
Journal:  Transl Res       Date:  2016-03-30       Impact factor: 7.012

5.  A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.

Authors:  Erin George; Hyoung Kim; Clemens Krepler; Brandon Wenz; Mehran Makvandi; Janos L Tanyi; Eric Brown; Rugang Zhang; Patricia Brafford; Stephanie Jean; Robert H Mach; Yiling Lu; Gordon B Mills; Meenhard Herlyn; Mark Morgan; Xiaochen Zhang; Robert Soslow; Ronny Drapkin; Neil Johnson; Ying Zheng; George Cotsarelis; Katherine L Nathanson; Fiona Simpkins
Journal:  JCI Insight       Date:  2017-01-12

6.  Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.

Authors:  Marcin P Iwanicki; Hsing-Yu Chen; Claudia Iavarone; Ioannis K Zervantonakis; Taru Muranen; Marián Novak; Tan A Ince; Ronny Drapkin; Joan S Brugge
Journal:  JCI Insight       Date:  2016-07-07

7.  Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube.

Authors:  Mark A Eckert; Shawn Pan; Kyle M Hernandez; Rachel M Loth; Jorge Andrade; Samuel L Volchenboum; Pieter Faber; Anthony Montag; Ricardo Lastra; Marcus E Peter; S Diane Yamada; Ernst Lengyel
Journal:  Cancer Discov       Date:  2016-10-07       Impact factor: 39.397

Review 8.  Fallopian tube initiation of high grade serous ovarian cancer and ovarian metastasis: Mechanisms and therapeutic implications.

Authors:  Tova M Bergsten; Joanna E Burdette; Matthew Dean
Journal:  Cancer Lett       Date:  2020-02-15       Impact factor: 8.679

9.  PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.

Authors:  Dima Ghannam-Shahbari; Eyal Jacob; Reli Rachel Kakun; Tanya Wasserman; Lina Korsensky; Ofir Sternfeld; Juliana Kagan; Debora Rosa Bublik; Sarit Aviel-Ronen; Keren Levanon; Edmond Sabo; Sarit Larisch; Moshe Oren; Dov Hershkovitz; Ruth Perets
Journal:  Oncogene       Date:  2018-01-30       Impact factor: 9.867

10.  Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors.

Authors:  Kevin M Elias; Megan M Emori; Thomas Westerling; Henry Long; Anna Budina-Kolomets; Fugen Li; Emily MacDuffie; Michelle R Davis; Alexander Holman; Brian Lawney; Matthew L Freedman; John Quackenbush; Myles Brown; Ronny Drapkin
Journal:  JCI Insight       Date:  2016-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.